Madrigal Pharmaceuticals, Inc. develops and commercializes therapies for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease that can progress to cirrhosis and liver failure. Its principal medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist approved by the FDA and European Commission for MASH with moderate to advanced fibrosis.
Company news regularly covers Rezdiffra sales and patient adoption, quarterly financial results, regulatory and clinical development updates, and pipeline expansion through licensed assets such as ARO-PNPLA3, a clinical-stage siRNA program targeting PNPLA3, and an oral GLP-1 receptor agonist program. Madrigal also issues recurring corporate-governance updates, including Nasdaq inducement awards under its employee equity plans.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.